You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

24 search results for: disease background

The Burden of Atopic Dermatitis in Children – The Impact of Persistent <b>Disease</b>

expert video

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease

1 min

Dermatology

Dr. Mark Koh explains how age at disease onset is linked to persistent disease.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

Atopic Dermatitis and Prurigo Nodularis: Distinct skin <b>disease</b>s with shared characteristics

Infographic

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics

5 min

Dermatology

An infographic exploring the shared and distinct clinical characteristics of atopic dermatitis and prurigo nodularis.

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct <b>Disease</b>s with Shared Characteristics

interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

5 min

Dermatology

Explore our interactive tool showcasing the unique and shared features, burden, and risk factors of atopic dermatitis and prurigo nodularis.

<b>Disease</b>-Specific Aspects of Itch in AD, PN, and CSU

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Atopic Dermatitis (AD) is a Type 2 Inflammatory <b>Disease</b>

videoanimation

Atopic Dermatitis (AD) is a Type 2 Inflammatory Disease

2 min

Dermatology

Discover the pathophysiological mechanisms involved in atopic dermatitis.

expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

2 min

Dermatology

Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.

expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

5 min

Dermatology

Exclusive interview with Prof. Lisa A. Beck delving into the potential for disease modification and the role of the microbiome in atopic dermatitis.

Infographic

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions

5 min

Dermatology

Explore how atopic dermatitis persists and advances, spanning childhood to adulthood via this informative infographic.

expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

5 min

Dermatology

Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.

expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children

13 min

Dermatology

Explore WCD 2023 ADVENT symposium's insights into managing short and long-term challenges of pediatric atopic dermatitis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwitzerlandChange country/region